Rapid mergers and acquisitions, frenzied supply chains: Pharma firms’ race for resilience | by Flavio Aliberti | December 2023

Explore Big Pharma M&A trends, their impact on supply chains and the urgent need for adaptability in the rapidly evolving healthcare landscape

Created with DALL-E

The success of integration between two or more organizations may not be immediately apparent and the process can be lengthy and cumbersome.

The right size financial performance and the true value of transactions is challenging for a reason diversity of business modelsvolatility of market situations, complexity of ownership structures and different technical reports and standards.

Just as it can take time for the impact of a new policy or law to be reflected in politics, it can be challenging to measure the success of mergers and acquisitions beyond initial enthusiasm generated by its public announcement.

Life science is no exception, and the ranking of pharmaceutical companies based on the number of collaborations and acquisitions completed in a decade can be dynamic and variable depending on the source.

However, an examination of partnerships, acquisitions and investments by large multinational firms over time trends reveal and evolutionary patterns in an ecosystem.

In this article, I will look at some M&A transactions to extrapolate how life sciences will soon change.

I will begin by examining the information available in last decadefinancial statements of major life sciences companies to get a quantitative idea of ​​how seriously they are taking this change.

I’ll finish exploring potential consequences of these changes, weaknesses and possible considerations for future transformation that may lead to a new ecosystem.

Source: Compiled from various online sources.

Pfizer’s journey in the pharmaceutical landscape shows strategic thinking and innovative foresight.

Leave a Comment